Variability of USP Lot P Prednisone Reference Standard Tablets - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Variability of USP Lot P Prednisone Reference Standard Tablets
The authors demonstrate that anecdotal reports of prednisone tablet variability are inaccurate.

Pharmaceutical Technology

Study 5. This study was a 28-laboratory collaborative study to determine the Apparatus 1 and Apparatus 2 PVT acceptance criteria for USP Lot P Prednisone RS Tablets (3). Participants were given the then-current Lot O tablets for assembly suitability testing and two sets of blinded tablets, one of which was Lot O and the other Lot P. Results reported here are for the two sets of blinded tablets. Results from this study, conducted in 2005, are compared with those obtained for Lots N and O in a collaborative study conducted in 2003.

Each laboratory was instructed to run two experiments of six tablets each. For each apparatus, two analysts were told to perform experiments using different equipment. After dropping experiments as outliers for failure to follow protocol or failure of assembly suitability (see Reference 3 for explanations), 38 experiments for Lot P using Apparatus 1 and 40 using Apparatus 2 were available for statistical analysis.

Figure 1. Lot P intra-experiment %CVs from Study 5.
These data were analyzed in a random-effects ANOVA similar to that for Studies 1 and 2. Random effects were laboratory, analyst, and experiment within analyst. The %CVs reported are from the residual variance from the ANOVAs. These intra-experiment %CVs include contributions from, at least, the tablets tested, variability among positions within the assemblies, assay, and position of the tablet when dropped in the vessel. The data shown in Figure 1 are based on pooling the intra-experiment results for each laboratory, as done for Study 1.


Table I: Intra-experiment variability of USP Lot P Prednisone and commercial tablets (Apparatus 2, Study 1).
Intra-experiment variability results from Study 1 are shown in Table I. For the USP Prednisone RS Tablets, the %CVs were consistently at or below 5% and had a combined value of 3.6%. The %CVs for the two commercially available tablets were much higher (ranitidine hydrochloride = 13.9% and metformin = 12.8%). Results from Study 2 are shown in Table II. Variability differs by assembly and shows fairly consistent results across site and analyst. Results from Study 3 are shown in Table III. In this study, again variability differed by assembly, even though assemblies alpha, gamma, and epsilon of Study 1 were the same as in Study 3. By switching the vessels used in assembly alpha with those in assembly gamma, analysts found that the high variability in assembly alpha was due to the vessels (2). Of note, the authors did see some low %CV for Apparatus 2 corresponding to those of Table I. Eight of 24 assembly–analyst combinations (before switching vessels) had a %CV <6% for Apparatus 2 (data not shown). Study IV's intra-experiment CVs for the vessels from the three manufacturers are shown in Table IV. Results vary considerably by vessel manufacturer.

Table II: Intra-experiment %CV (Apparatus 2, Study 2).
Table V shows the results from Study V for the intra-experiment %CV combined across all participating laboratories. Results remain fairly consistent across the three lots. Table V does not show the variability among laboratories in the %CV. This is shown in Figure 1 for Lot P. In Figure 1, the median values are 8.0% for Apparatus 1 and 6.5% for Apparatus 2. That is, half the laboratories had an intra-experiment %CV with Apparatus 2 of no more than 6.5%. The larger values of Table V are a result of the inclusion of the results from the laboratories with the larger values at the top of Figure 1, many of which are greater than 10% and thus are considered highly variable (16).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here